VYCO 最新10-Q变化
将 VYCO 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-15
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +14 | −6 | ~13 | 11 |
| 控制与程序 | 无段落级文字变化 | 0 | 0 | 0 | 6 |
| 法律诉讼 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 9 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、风险因素
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Comparison of the Six Months Ended June 30, 2026 to the Six Months Ended June 30, 2025
Vycor Medical recorded revenue of $841,665 from the sale of its products for the six months ended June 30, 2026, a decrease of $58,643, or 7%, over the same period in 2025, the majority of the decrease being from international markets, which can often be lumpy with large orders sometimes falling in …
NovaVision recorded revenues of $35,139 for the six months ended June 30, 2026, an increase of $2,716 over the same period in 2025. Gross margin was 95%, compared to 93% for the same period in 2025.
Research & Development expenses were $0 for the six months ended June 30, 2026 compared to $9,963 for the same period in 2025, reflected new product development in the Vycor Medical division in 2025.
Selling, general and administrative expenses decreased by $57,665 to $638,076 for the six months ended June 30, 2026 from $695,741 for the same period in 2025. Included within Selling, General and Administrative Expenses are non-cash charges for stock-based compensation as the result of amortizing n…
相对上期删除的文字 · 来源:10-Q · 2026-05-15
The following table shows liquidity data as of March 31, 2026 and December 31, 2025:
Accounts receivable, inventory and other current assets $477,413 $476,440 $973
The following table shows cash flow for the periods ended March 31, 2026 and 2025:
Operating Activities. Cash provided by (used in) operating activities comprises net loss adjusted for non-cash items and the effect of changes in working capital and other activities.
The following table shows the principal components of cash provided by (used in) operating activities during the three months ended March 31, 2026 and 2025, with a commentary of changes during the periods and known or anticipated future changes:
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议